Updated reviews issued for oseltamivir, zanamivir use in flu

Updated reviews issued for oseltamivir, zanamivir use in flu

(HealthDay)—Oseltamivir and zanamivir reduce the time to symptomatic improvement in influenza by about half a day, but evidence to support claims of reduced admissions to hospital or complications of influenza is lacking, according to two systematic reviews of regulatory information published online April 10 in BMJ.

Tom Jefferson, Ph.D., from the Cochrane Acute Respiratory Infections Group in Rome, and colleagues conducted a systematic review of clinical study reports and regulatory information to describe the potential benefits and harms of . Twenty-three trials were included in a reliability and completeness screen and 20 in a formal analysis. The researchers found that oseltamivir reduced the time to first alleviation of symptoms by 16.8 hours in treatment trials on adults, and had an effect in some children. In prophylaxis trials, oseltamivir reduced symptomatic influenza by 55 percent in participants, but had no significant effect on asymptomatic influenza and no indication of a reduction in transmission. In treatment
trials there was no difference in admissions to hospital in adults (risk difference, 0.15 percent; 95 percent confidence interval, −0.91 to 0.78 percent; P = 0.84)
and sparse data in children and for prophylaxis.

Carl J. Heneghan, M.D., from the University of Oxford in the United Kingdom, and colleagues conducted a of clinical study reports and regulatory information to describe the potential benefits and harms of zanamivir. Twenty-eight trials were assessed for appropriate study design and 26 were included in a formal analysis. The researchers found that in adults, zanamivir correlated with 0.60-day reduction in the time to first alleviation of symptoms of influenza-like illness. Zanamivir prophylaxis correlated with a reduction in symptomatic influenza in individuals (risk difference, 1.98 percent).

"Zanamivir reduces the time to symptomatic improvement in adults (but not in children) with influenza-like illness by just over half a day, although this effect might be attenuated by symptom relief medication," Heneghan and colleagues write. "We found no evidence that zanamivir reduces the risk of complications of , particularly pneumonia, or the risk
of hospital admission or death."

Several authors from both studies disclosed financial ties to pharmaceutical companies, including GlaxoSmithKline, the manufacturer of (Relenza).

More information: Full Text - Jefferson
Full Text - Heneghan
Editorial 1
Editorial 2

add to favorites email to friend print save as pdf

Related Stories

Continuing uncertainties surround anti-influenza drug

Jan 18, 2012

Incomplete availability of data has hampered a thorough assessment of the evidence for using the anti-influenza drug oseltamivir, a Cochrane Review has found. However, after piecing together information from over 16,000 pages ...

New research assesses use of Tamiflu, Relenza to prevent flu

Aug 03, 2009

Two common anti-influenza drugs — Relenza and Tamiflu — appear equally effective at preventing common flu symptoms when given before infection, say researchers from the Stanford University School of Medicine. However, ...

Recommended for you

Sri Lanka celebrates two years without malaria

1 minute ago

Sri Lanka has not reported a local case of malaria since October 2012, according to the Sri Lankan Anti-Malarial Campaign. If it can remain malaria-free for one more year, the country will be eligible to apply to the World ...

Poll: Many doubt hospitals can handle Ebola

3 hours ago

A new poll finds most Americans have some confidence that the U.S. health care system will prevent Ebola from spreading in this country, but they're not so sure their local hospital can safely handle a patient.

Number of Ebola cases nears 10,000

4 hours ago

The number of people with Ebola is set to hit 10,000 in West Africa, the World Health Organization said, as the scramble to find a cure gathered pace.

'Breath test' shows promise for diagnosing fungal pneumonia

4 hours ago

Many different microbes can cause pneumonia, and treatment may be delayed or off target if doctors cannot tell which bug is the culprit. A novel approach—analyzing a patient's breath for key chemical compounds made by the ...

User comments